Annual report pursuant to Section 13 and 15(d)

Note 21 - Segments (Tables)

v3.8.0.1
Note 21 - Segments (Tables)
12 Months Ended
Dec. 31, 2017
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Year Ended December 31, 2017
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Tc99m tilmanocept sales revenue:
                               
United States
  $
    $
    $
    $
 
International
   
     
     
     
 
Tc99m tilmanocept license revenue
   
100,000
     
     
     
100,000
 
Tc99m tilmanocept royalty revenue
   
9,126
     
     
     
9,126
 
Grant and other revenue
   
1,506,232
     
195,079
     
     
1,701,311
 
Total revenue
   
1,615,358
     
195,079
     
     
1,810,437
 
Cost of goods sold
   
3,651
     
     
     
3,651
 
Research and development expenses, excluding depreciation and amortization
   
3,784,255
     
729,587
     
     
4,513,842
 
Selling, general and administrative expenses, excluding depreciation and amortization
(a)
   
     
34,484
     
10,895,301
     
10,929,785
 
Depreciation and amortization
(b)
   
     
     
240,166
     
240,166
 
L
oss from operations
(c)
   
(2,172,548
)
   
(568,992
)
   
(11,135,467
)
   
(13,877,007
)
Other income (expense)
(d)
   
     
     
(3,912,679
)
   
(3,912,679
)
Benefit from income taxes
   
496,127
     
129,936
     
3,436,426
     
4,062,489
 
L
oss from continuing operations
   
(1,676,421
)
   
(439,056
)
   
(11,611,720
)
   
(13,727,197
)
Income
from discontinued operations, net of tax effect
   
88,673,053
     
     
     
88,673,053
 
Net income (loss)
   
86,996,632
     
(439,056
)
   
(11,611,720
)
   
74,945,856
 
Total assets, net of depreciation and amortization:
                               
United States
  $
13,065,871
    $
49,001
    $
7,634,237
    $
20,749,109
 
International
   
30,476
     
     
1,851
     
32,327
 
Capital expenditures
   
     
     
33,690
     
33,690
 
Year Ended December 31, 2016
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Tc99m tilmanocept sales revenue:
                               
United States
  $
    $
    $
    $
 
International
   
39,601
     
     
     
39,601
 
Tc99m tilmanocept license revenue
   
1,795,625
     
     
     
1,795,625
 
Grant and other revenue
   
3,011,642
     
124,766
     
     
3,136,408
 
Total revenue
   
4,846,868
     
124,766
     
     
4,971,634
 
Cost of goods sold, excluding depreciation and amortization
   
62,260
     
     
     
62,260
 
Research and development expenses, excluding depreciation and amortization
   
6,375,929
     
762,151
     
     
7,138,080
 
Selling, general and administrative expenses, excluding depreciation and amortization
(a)
   
     
63,158
     
7,403,329
     
7,466,487
 
Depreciation and amortization
(b)
   
56,317
     
     
397,232
     
453,549
 
L
oss from operations
(c)
   
(1,647,638
)
   
(700,543
)
   
(7,800,561
)
   
(10,148,742
)
Other income (expense), excluding equity in the loss of R-NAV, LLC
(d)
   
     
     
2,786,007
     
2,786,007
 
Equity in the loss of R-NAV, LLC
   
     
     
(15,159
)
   
(15,159
)
L
oss from continuing operations
   
(1,647,638
)
   
(700,543
)
   
(5,029,713
)
   
(7,377,894
)
Loss from discontinued operations, net of tax effect
   
(6,931,137
)
   
     
     
(6,931,137
)
Net loss
   
(8,578,775
)
   
(700,543
)
   
(5,029,713
)
   
(14,309,031
)
Total assets, net of depreciation and amortization:
                               
United States
  $
3,815,271
    $
15,075
    $
8,498,797
    $
12,329,143
 
International
   
131,752
     
     
781
     
132,533
 
Capital expenditures
   
     
     
1,847
     
1,847
 
Year Ended December 31, 2015
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Tc99m tilmanocept sales revenue:
                               
United States
  $
    $
    $
    $
 
International
   
19,075
     
     
     
19,075
 
Tc99m tilmanocept license revenue
   
1,133,333
     
     
     
1,133,333
 
Grant and other revenue
   
1,860,953
     
     
     
1,860,953
 
Total revenue
   
3,013,361
     
     
     
3,013,361
 
Cost of goods sold, excluding depreciation and amortization
   
3,226
     
     
     
3,226
 
Research and development expenses, excluding depreciation and amortization
   
9,831,834
     
730,895
     
     
10,562,729
 
Selling, general and administrative expenses, excluding depreciation and amortization
(a)
   
     
123,884
     
10,242,066
     
10,365,950
 
Depreciation and amortization
(b)
   
232,091
     
     
290,105
     
522,196
 
Loss from operations
(c)
   
(7,053,790
)
   
(854,779
)
   
(10,532,171
)
   
(18,440,740
)
Other income (expense), excluding equity in the loss of R-NAV, LLC
(d)
   
     
     
(4,298,604
)
   
(4,298,604
)
Equity in the loss of R-NAV, LLC
   
     
     
(305,253
)
   
(305,253
)
L
oss from continuing operations
   
(7,053,790
)
   
(854,779
)
   
(15,136,028
)
   
(23,044,597
)
Income
(loss) from discontinued operations,
net of tax effect
(e)
   
(5,713,598
)
   
     
1,194,660
     
(4,518,938
)
Net loss
   
(12,767,388
)
   
(854,779
)
   
(13,941,368
)
   
(27,563,535
)
Total assets, net of depreciation and amortization:
                               
United States
  $
4,161,029
    $
    $
10,391,805
    $
14,552,834
 
International
   
410,666
     
     
1,013
     
411,679
 
Capital expenditures
   
26,589
     
     
12,412
     
39,001